Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 4 for:    Edmonston Strain of Measles Virus,
Previous Study | Return to List | Next Study

UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2016 by University of Arkansas
Information provided by (Responsible Party):
University of Arkansas Identifier:
First received: July 2, 2014
Last updated: October 6, 2016
Last verified: October 2016
The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide

Condition Intervention Phase
Multiple Myeloma
Drug: MV-NIS
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by University of Arkansas:

Primary Outcome Measures:
  • The effectiveness of MV-NIS therapy as measured by the International Myeloma Working Group (IMWG) guidelines [ Time Frame: 1 year ]
    The primary objective of this study is to assess the effectiveness of MV-NIS therapy for people with relapsed/refractory myeloma when given with cyclophosphamide

Estimated Enrollment: 16
Study Start Date: March 2015
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MV-NIS + Cyclophosphamide Drug: MV-NIS
one dose in conjunction with a 4 day course intravenously
Other Name: Recombinant Edmonston measles virus with human NIS gene

Detailed Description:
The drug used in this trial is a modified version of the measles virus used to vaccinate children. The virus has been altered by having an extra gene (piece of DNA) added to it to allow a protein called NIS to be inserted into it. NIS is normally found in the thyroid gland ( a small gland in the neck) and helps the body concentrate iodine. Having this additional gene will make it possible to track where the virus goes in the body.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed patients must have a confirmed MM diagnosis with high-risk disease as defined by GEP70 risk score ≥ 0.66 or GEP80 gene score of ≥ 2.48 or metaphase cytogenetic abnormalities or LDH ≥ 360 U/L due to MM (Rule out hemolysis, infection and contact PI for clarification if any doubt). Patients must have relapsed after auto-PBSCT followed by further chemotherapy
  • ≥2 months must have elapsed after the last peripheral blood stem cell transplant prior to enrollment
  • Zubrod ≤ 2, unless solely due to symptoms of MM-related (bone) disease
  • Patients must have a platelet count of ≥ 20,000/µL within 45 days of registration, unless lower levels are explained by extensive BM plasmacytosis or extensive prior therapy
  • Patients must be at least 18 years of age and not older than 75 years of age at the time of registration
  • Participants must have preserved renal function as defined by a serum creatinine level of ≤ 3 mg/dL within 45 days of registration
  • Participants must have an ejection fraction by ECHO or MUGA scan ≥ 40% within 45 days prior to registration
  • Patients must have adequate pulmonary function studies > 50% of predicted on mechanical aspects (FEV1, etc) and diffusion capacity (DLCO) > 50% of predicted within 45 days prior to registration. If the patient is unable to complete pulmonary function tests due to MM related pain or condition, exception may be granted
  • Patients must have signed an IRB-approved informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization form
  • Patients must have anti-MV IgG titer of ≤ 0.5U/mL (Mayo clinic assay). Mayo Clinic will also assay the patients' IgM titer and perform a neutralizing antibody plaque-assay to determine recent MV exposure and the ability of the patients' circulating antibodies to inhibit MV propagation on Vero cells, respectively. While these tests are additional indicators of patient eligibility, final enrollment decision will be determined by IgG levels

Exclusion Criteria:

  • Patients may not be positive for the Human Immunodeficiency Virus (HIV)
  • History of poorly controlled hypertension, diabetes mellitus, or any other serious medical illness or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol or could be considered to be an exclusion criterion deemed by the PI
  • Patients must not have prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has not received treatment for one year prior to enrollment. Other cancers will only be acceptable if the patient's life expectancy exceeds three years as determined by the PI
  • Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy test documented within one week of registration. Women/men of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
  • Exposure to household contacts ≤ 15 months old or household contact with known immunodeficiency
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02192775

Contact: Nathan M Petty 501-526-6990 ext 2435

United States, Arkansas
University of Arkansas for Medical Science Recruiting
Little Rock, Arkansas, United States, 72205
Contact: Nathan M Petty    501-526-6990 ext 2435   
Sub-Investigator: Faith Davies, MD         
Sub-Investigator: Michele Fox, MD         
Sub-Investigator: Gareth Morgan, MD, PhD         
Sub-Investigator: Maurizio Zangari, MD         
Sub-Investigator: Atul Kothari, MD         
Sub-Investigator: Carolina Schinke, MD         
Sub-Investigator: Juan Crescencio, MD         
Sub-Investigator: Mary Burgess, MD         
Sub-Investigator: Meera Mohan, MD         
Sub-Investigator: Muthukumar Radhakrishnan, MD         
Sub-Investigator: Pankaj Mathur, MD         
Sub-Investigator: Sharmilan Thanendrajan, MD         
Sub-Investigator: Sandra Susanibar-Adaniya, MD         
Sub-Investigator: Shadiqul Hoque, MD         
Sponsors and Collaborators
University of Arkansas
Principal Investigator: Frits Van Rhee, MD, Ph.D University of Arkansas
  More Information

Responsible Party: University of Arkansas Identifier: NCT02192775     History of Changes
Other Study ID Numbers: 203081
Study First Received: July 2, 2014
Last Updated: October 6, 2016

Keywords provided by University of Arkansas:
Measles virus
Sodium Iodide Symporter
Refractory multiple myeloma

Additional relevant MeSH terms:
RNA Virus Infections
Virus Diseases
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Morbillivirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Myeloablative Agonists processed this record on April 28, 2017